Abstract: Embodiments of the present invention facilitate efficient and effective increased memory cell density configuration. In one embodiment, a semiconductor device comprises: a first pillar magnetic tunnel junction (pMTJ) memory cell that comprises a first pMTJ located in a first level in the semiconductor device; and a second pillar magnetic tunnel junction (pMTJ) memory cell that comprises a second pMTJ located in a second level in the semiconductor device, wherein the second pMTJ location with respect to the first pMTJ is coordinated to comply with a reference pitch for the memory cell. A reference pitch is associated a first switch coupled to the first pMTJ and the second pitch reference component is a second switch coupled to the second pMTJ. The first switch and second switch can be transistors. The reference pitch coordination facilitates reduced pitch between memory cells and increased information storage capacity of bits per memory device area.

Abstract: A wire management device for storing an earphone wire having a signal terminal and a pair of speakers includes an elongated frame having first and second ends, the frame having a first channel to hold a first wrapped part of the wire, first and second beaks respectively arranged at the first and second ends of the frame to stay the terminal of the wire, and first and second wings respectively branching from neighboring positions of the first and second ends the frame, the first and second wings are, respectively, bent toward the first and second ends of the frame for wrapping the wire, wherein at least one of the wings includes a clamping portion to clamp a last wrapped part of the wire.

Abstract: A wire management device for storing an earphone wire having a signal terminal and a pair of speakers includes an elongated frame having first and second ends, the frame having a first channel to hold a first wrapped part of the wire, first and second beaks respectively arranged at the first and second ends of the frame to stay the terminal of the wire, and first and second wings respectively branching from neighboring positions of the first and second ends the frame, the first and second wings are, respectively, bent toward the first and second ends of the frame for wrapping the wire, wherein at least one of the wings includes a clamping portion to clamp a last wrapped part of the wire.

Abstract: Systems and methods are provided for lifting hydrocarbons from reservoirs. A method includes injecting a heat carrier fluid comprising steam, hot water, or both into a first well and injecting an organic compound into a second well. The organic compound is selected to vaporize to a gas from the heat provided by the heat carrier fluid, forcing produced fluids to the surface. The produced fluids are collected at the surface.

Abstract: Systems and methods are provided for lifting hydrocarbons from reservoirs. A method includes injecting a heat carrier fluid comprising steam, hot water, or both into a first well and injecting an organic compound into a second well. The organic compound is selected to vaporize to a gas from the heat provided by the heat carrier fluid, forcing produced fluids to the surface. The produced fluids are collected at the surface.

Abstract: A fibrinolytically active metalloproteinase polypeptide (called “novel acting thrombolytic”) which is useful for blood clot lysis in vivo and methods and materials for its production by recombinant expression are described.

Abstract: The present invention provides Fibroblast Growth Factor Receptor-Like (FGFR-L) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing FGFR-L polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with FGFR-L, polypeptides.

Abstract: An Extraordinary Magnetoresistive Sensor (EMR Sensor) having wide voltage lead tabs for reduced noise and increased signal to noise ratio. The leads can be formed in a triad structure, wherein a pair of voltage leads is located at either side of a current lead, or can be formed in a diad structure having a single voltage lead located at one side of a current lead.

Abstract: An extraordinary magnetoresistive device EMR having a discontinuous shunt structure. The discontinuous shunt structure improves the linearity of response of the EMR device. The EMR device includes a EMR heterostructure that includes an EMR active layer. The heterostructure can include first, second and third semiconductor layers, with the second layer being sandwiched between the first and third layers. The middle, or second semiconductor layer provides a two dimensional electron gas. The heterostructure has first and second opposed sides, with a pair of voltage leads and a pair of current leads connected with the first side of the structure. The discontinuous shunt structure is connected with the second side of the structure and may be in the form of a series of discontinuous, electrically conductive elements, such as semi-spherical gold elements.

Abstract: The present invention broadly relates to the field of protein modification, and, more specifically, the attachment of water soluble polymers to novel erythropoietin stimulating protein (NESP).

Abstract: Chimeric molecules comprising receptor activator of NF-?B ligand (RANKL) antibodies and parathyroid hormone/parathyroid hormone-related protein (PTH/PTHrP) peptides are described. Compositions and methods for the treatment of bone diseases are also described.

Abstract: The present invention concerns fusion of Fc domains with biologically active peptides and a process for preparing pharmaceutical agents using biologically active peptides. In this invention, pharmacologically active compounds are prepared by selecting a peptide that modulates the activity of a protein of interest and preparing a pharmacologic agent having an Fc domain covalently linked to the peptide. Linkage to the Fc domain increases the half-life of the peptide, which otherwise would be quickly degraded in vivo. The peptide can be selected, for example, by phage display, E. coli display, ribosome display, RNA-peptide screening, yeast-based screening, chemical-peptide screening, rational design, or protein structural analysis.

Abstract: Methods are disclosed for producing highly doped semiconductor materials. Using the invention, one can achieve doping densities that exceed traditional, established carrier saturation limits without deleterious side effects. Additionally, highly doped semiconductor materials are disclosed, as well as improved electronic and optoelectronic devices/components using said materials. The innovative materials and processes enabled by the invention yield significant performance improvements and/or cost reductions for a wide variety of semiconductor-based microelectronic and optoelectronic devices/systems. Materials are grown in an anion-rich environment, which, in the preferred embodiment, are produced by moderate substrate temperatures during growth in an oxygen-poor environment.

Abstract: The present invention provides novel VGF polypeptides and selective binding agents. The invention also provides host cells and methods for producing VGF polypeptides. The invention further provides VGF pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, conditions, and disorders associated with VGF polypeptides.

Abstract: The present invention broadly relates to the field of protein modification, and, more specifically, the attachment of water soluble polymers to novel erythropoietin stimulating protein (NESP).

Abstract: The present invention concerns fusion of Fc domains with Ang-2 binding peptides and a process for preparing such molecules. In this invention, pharmacologically active compounds are prepared by a process comprising (a) selecting at least one random peptide that binds to Ang-2; and (b) preparing a pharmacologic agent comprising an Fc domain covalently linked to at least one amino acid of the selected peptide. Linkage to the vehicle increases the half-life of the peptide, which otherwise would be quickly degraded in vivo. The preferred vehicle is an Fc domain. The peptide can be selected, for example, by phage display, E. coli display, ribosome display, RNA-peptide screening, yeast-based screening, chemical-peptide screening, rational design, or protein structural analysis.

Abstract: The present invention relates to certain biologically active peptides and polypeptides which can be used as therapeutics or prophylactics against diseases or disorders linked to NGF as the causative agent. In one aspect of the present invention, pharmacologically active polypeptides comprising peptides linked to one or more Fc domains are provided.

Abstract: A novel metalloproteinase inhibitor, analogs thereof, polynucleotides encoding the same, and methods of production, are disclosed. Pharmaceutical compositions and methods of treating disorders caused by excessive amounts of metalloproteinase are also disclosed.

Abstract: The in vivo circulating life and/or absorption of cationic therapeutic proteins, including but not limited to basic proteins such as NT-3 and BDNF, can be increased by generating analogs that have a lower isoelectric point and, preferably, also a lower protein charge relative to the protein of native sequence.

Abstract: The present invention concerns fusion of Fc domains with biologically active peptides and a process for preparing pharmaceutical agents using biologically active peptides. In this invention, pharmacologically active compounds are prepared by a process comprising: a) selecting at least one peptide that modulates the activity of a protein of interest; and b) preparing a pharmacologic agent comprising an Fc domain covalently linked to at least one amino acid of the selected peptide. Linkage to the vehicle increases the half-life of the peptide, which otherwise would be quickly degraded in vivo. The preferred vehicle is an Fc domain. The peptide can be selected, for example, by phage display, E. coli display, ribosome display, RNA-peptide screening, yeast-based screening, chemical-peptide screening, rational design, or protein structural analysis.